- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01882361
Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
1.2.1 Primary and Secondary Outcome Measures
Primary outcomes are:
1) Opiate positive urine tests; 2) HIV injecting risk.
Secondary outcomes are:
1) Time to relapse; 2) HIV sex risk; 3) Proportion of appointments kept; 6) Psychiatric symptoms; 7) Opioid craving; 8) Self-reported drug use; 9) Money spent for drugs; 10) Employment; 11) Arrests; 12) Overall adjustment; 12) Adverse events.
Hypotheses are that:
- Primary outcomes will significantly favor the 48-week Vivitrol condition;
- Five or more secondary outcomes will favor the 48-week condition; none will favor the 24-week condition.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation, 119002
- Federal Medical Research Center for Psychiatry and Narcology (FMRC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-negative men and women 18 years of age or older who meet the Diagnostic and Statistical Manual of Mental Disorders 4th edition-Text Revision (DSM- IV-TR) criteria for opioid dependence
- Must be voluntarily seeking treatment for opioid dependence, with injection heroin as the drug and administration route of choice
- Must report sharing injection equipment during the past year
- Must have successfully completed inpatient detoxification at the Federal Medical Research Center for Psychiatry and Narcology (FMRCPN)
- Must have no current evidence of physiologic dependence
- Must have a stable address in Moscow with a telephone number where they can be reached
- If female, must have a negative pregnancy test and use of medically acceptable contraception if of childbearing age
- Must be able to provide informed consent as judged by the ability to read the consent and correctly answer 9 out of 10 questions about the study on a quiz
Exclusion Criteria:
- No current condition of psychosis (schizophrenia,paranoid disorder, mania)
- No history of major psychiatric disorders such as Schizophrenia, Major Depression with suicidal attempts, Bipolar I, uncontrolled epilepsy or other seizure disorder
- No current dependence (within the past year) to drugs other than prescription opiates or heroin, caffeine, marijuana, or nicotine based on the Diagnostic and Statistical Manual of Mental Disorders-Text Revision (DSM -IV-TR) criteria
- No current alcohol dependence or alcohol use disorder that would preclude successful completion of study procedures
- No current suicidal or homicidal ideation requiring immediate attention as determined at baseline assessment
- No cognitive impairment with inability to read and understand the consent
- No significant laboratory abnormality such as haemoglobin <10, hepatic transaminase levels >3 times upper limit of normal or serum creatinine that is >1.5 times upper limit of normal
- No legal charges with impending incarceration
- No concurrent participation in another treatment study
- Cannot be scheduled for surgery or be likely to require opioids for pain control in next 2 years
- Not currently taking naltrexone or currently receiving other treatment (pharmacological or behavioral) for drug dependence or currently receiving psychoactive medication
- Cannot have had receipt of any approved or investigational depot product administered into the gluteal muscle within 6 months before screening
- Cannot be on any excluded medication at screening or be anticipating the use of an excluded medication during the study period
- Cannot have participated in a clinical trial of a pharmacological agent within 30 days prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: injectable naltrexone
One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
|
Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month.
After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later.
Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
Other Names:
|
Placebo Comparator: placebo injection for naltrexone
placebo comparator injection starting at week 24 in a 48-week trial.
|
this placebo has no specific pharmacological activity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opiate positive urine tests
Time Frame: 12 months
|
Reduction in drug use as seen by the primary urine outcomes will significantly favor the 48-week Vivitrol condition
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV sex risk
Time Frame: 12 months
|
Participants will show significant HIV sex risk behaviors in the 48-week vivitrol condition.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events
Time Frame: 12 months
|
No increase in known adverse events for the vivitrol arm as seen in other studies.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: George E Woody, MD, University of Pennsylvania
- Principal Investigator: Tatiana Klimenko, MD, PhD, Federal Medical Research Center for Psychiatry and Narcology (FMRC)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Narcotic-Related Disorders
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Alcohol Deterrents
- Naltrexone
Other Study ID Numbers
- 816019
- R01DA033670 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusSpain, France, Germany
Clinical Trials on injectable naltrexone
-
University of Colorado, DenverWithdrawnAlcohol Use Disorder
-
State University of New York - Upstate Medical...CephalonCompletedAlcohol Dependence | Schizophrenia | Schizoaffective Disorders | Bipolar DisordersUnited States
-
Alkermes, Inc.Terminated
-
University of PennsylvaniaNot yet recruitingOpioid Dependence
-
Centre for Addiction and Mental HealthUnknown
-
Duke UniversityAlkermes, Inc.; Laura and John Arnold Foundation; FHR (Fellowship Health Resources... and other collaboratorsCompletedOpioid-Related DisordersUnited States
-
Alkermes, Inc.Completed
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)Completed
-
Alkermes, Inc.Completed